Trustworthy development and commercial manufacturing of CELL&GENE therapies

On december 1st 2023, Seqens completed the acquisition of CELLforCURE.

Originally a versatile CELL&GENE CDMO, CELLforCURE gained thorough experience in commercial CAR-T cells manufacturing. With 2 200m2 GMP production areas, 6 equipped production suites and 180 seasoned highly skilled experts, CELLforCURE offers versatile and flexible capacities.

Located in France, 20km away from the Paris Orly Airport, CELLforCURE is an EMA approved production site and is compliant with FDA standards. The site brings analytical, development and regulatory services to serve client needs across the overall product life cycle.

CELLforCURE teams aim at partnering with innovators to develop and manufacture CELL&GENE therapies for today and tomorrow.